

Jean-François Dufour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6253456/publications.pdf>

Version: 2024-02-01

341
papers

31,046
citations

12330

69
h-index

4991

167
g-index

430
all docs

430
docs citations

430
times ranked

29088
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	12.1	62
2	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
3	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548.	3.7	66
4	HCV disease burden and population segments in Switzerland. <i>Liver International</i> , 2022, 42, 330-339.	3.9	14
5	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	4.9	20
6	Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two-dimensional shear wave elastography in non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 102-111.	3.9	13
7	Humoral response to SARS-CoV-2 infection among liver transplant recipients. <i>Gut</i> , 2022, 71, 746-756.	12.1	11
8	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 1001-1012.	3.7	54
9	The <sc>NAFLD–MAFLD</sc> debate: Is there a Consensus–Consensus methodology?. <i>Liver International</i> , 2022, 42, 742-748.	3.9	15
10	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	8.1	135
11	The MELD upgrade exception: a successful strategy to optimize access to liver transplantation for patients with high waiting list mortality. <i>Hpb</i> , 2022, 24, 1168-1176.	0.3	2
12	PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4305.	4.1	28
13	Breakthroughs in hepatology. <i>Journal of Hepatology</i> , 2022, 76, 1247-1248.	3.7	0
14	COVID-19 and liver disease. <i>Gut</i> , 2022, 71, 2350-2362.	12.1	48
15	Current therapies and new developments in NASH. <i>Gut</i> , 2022, 71, 2123-2134.	12.1	82
16	Coincidence of NOD2-Associated Autoinflammatory Disease (Yao Syndrome) and HCV Infection With Fatal Consequences. <i>Journal of Clinical Rheumatology</i> , 2021, 27, S592-S594.	0.9	4
17	Redefining fatty liver disease: an international patient perspective. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 73-79.	8.1	127
18	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 24-39.	17.8	174

#	ARTICLE	IF	CITATIONS
19	High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 828-836.	3.9	19
20	Systemic therapy of advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2021, 17, 1237-1251.	2.4	31
21	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. <i>Liver Cancer</i> , 2021, 10, 360-369.	7.7	25
22	Malnutrition and Alcohol in Patients Presenting with Severe Complications of Cirrhosis After Laparoscopic Bariatric Surgery. <i>Obesity Surgery</i> , 2021, 31, 2817-2822.	2.1	8
23	Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. <i>Nature</i> , 2021, 592, 444-449.	27.8	233
24	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
25	A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?. <i>Cancers</i> , 2021, 13, 1412.	3.7	26
26	Laparoscopic Liver Findings – An Instructional Collection for Endoscopic Surgeons. <i>Journal of Laparoendoscopic & Advanced Surgical Techniques Part B, Videoscopy</i> , 2021, 31, .	0.2	0
27	Dietary Interventions in Liver Diseases: Focus on MAFLD and Cirrhosis. <i>Current Hepatology Reports</i> , 2021, 20, 61-76.	0.9	2
28	Calcium transfer between endoplasmic reticulum and mitochondria in liver diseases. <i>FEBS Letters</i> , 2021, 595, 1411-1421.	2.8	13
29	The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors – A targeted literature review. <i>Endocrine and Metabolic Science</i> , 2021, 3, 100089.	1.6	35
30	Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib. <i>JGH Open</i> , 2021, 5, 864-870.	1.6	1
31	Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention. <i>Journal of Hepatology</i> , 2021, 75, 1217-1227.	3.7	57
32	COVID-19 in Liver Transplant Recipients: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 4015.	2.4	19
33	Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 835-856.	17.8	183
34	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
35	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021, 75, 865-878.	3.7	111
36	Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis. <i>Cancers</i> , 2021, 13, 4983.	3.7	17

#	ARTICLE	IF	CITATIONS
37	NTCP: a pharmacological target for multiple liver conditions. <i>Gut</i> , 2021, , gutjnl-2021-325917.	12.1	1
38	Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1896-1918.	2.0	5
39	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. <i>Hepatology</i> , 2020, 72, 88-102.	7.3	76
40	Exercise Improves Outcomes of Surgery on Fatty Liver in Mice. <i>Annals of Surgery</i> , 2020, 271, 347-355.	4.2	5
41	Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1151-1158.	3.9	17
42	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , 2020, 69, 764-780.	12.1	112
43	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	1.8	71
44	Nuclear deformation mediates liver cell mechanosensing in cirrhosis. <i>JHEP Reports</i> , 2020, 2, 100145.	4.9	35
45	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in human obesity-related non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 73, S20-S21.	3.7	0
46	A transcriptomic signature predicting fibrosis progression in a large European cohort of patients with histologically characterised NAFLD. <i>Journal of Hepatology</i> , 2020, 73, S109-S110.	3.7	0
47	Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3830.	3.7	47
48	High subcutaneous tissue density correlates negatively with survival in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, S383-S384.	3.7	0
49	Absence of histidine triad nucleotide binding protein-2 (HINT-2) triggers mitochondrial dysfunction and aggravates steatosis. <i>Journal of Hepatology</i> , 2020, 73, S679-S680.	3.7	0
50	Bidimensional shear wave elastography of the rectus femoris muscle in patients with cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, S696.	3.7	1
51	Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. <i>Gut</i> , 2020, 69, 1877-1884.	12.1	127
52	Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice. <i>Cancers</i> , 2020, 12, 1407.	3.7	27
53	Immunotherapy as a Downstaging Therapy for Liver Transplantation. <i>Hepatology</i> , 2020, 72, 1488-1490.	7.3	59
54	Antitumour necrosis factor- α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000349.	2.7	23

#	ARTICLE	IF	CITATIONS
55	COVID-19 in an international European liver transplant recipient cohort. <i>Gut</i> , 2020, 69, 1832-1840.	12.1	120
56	S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. <i>Gut</i> , 2020, 69, 1841-1854.	12.1	50
57	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	3.7	2,171
58	Changing TACTICS in intermediate HCC: TACE plus sorafenib. <i>Gut</i> , 2020, 69, 1374-1376.	12.1	9
59	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	3.7	279
60	Clinical Diagnosis and Staging of Intrahepatic Cholangiocarcinoma. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 481-489.	0.9	37
61	Medical management of metabolic and cardiovascular complications after liver transplantation. <i>World Journal of Gastroenterology</i> , 2020, 26, 2138-2154.	3.3	25
62	Intricate interpretation of etiology-specific outcome comparison in patients with hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 238-239.	8.9	1
63	Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 238-246.	4.7	5
64	Stereotactic image-guided microwave ablation of hepatocellular carcinoma using a computer-assisted navigation system. <i>Liver International</i> , 2019, 39, 1975-1985.	3.9	50
65	FRI-113-Matrix stiffness modulates the phenotype of hepatic cells in cirrhosis and modifies the sinusoidal effects of statins. <i>Journal of Hepatology</i> , 2019, 70, e437.	3.7	1
66	Nicotinamide and NAFLD: Is There Nothing New Under the Sun?. <i>Metabolites</i> , 2019, 9, 180.	2.9	18
67	Is ex vivo liver resection and autotransplantation a valid alternative treatment for end-stage hepatic alveolar echinococcosis in Europe?. <i>Journal of Hepatology</i> , 2019, 70, 1030-1031.	3.7	23
68	FRI-302-Impact of exercise on advanced fibrotic stage of NASH and liver carcinogenesis. <i>Journal of Hepatology</i> , 2019, 70, e528.	3.7	0
69	THU-497-Molecular fingerprint of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2019, 70, e379.	3.7	0
70	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 473-485.	3.7	62
71	GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>Journal of Hepatology</i> , 2019, 70, e5.	3.7	39
72	Hepatic gene expression in mouse models of non-alcoholic fatty liver disease after acute exercise. <i>Hepatology Research</i> , 2019, 49, 637-652.	3.4	8

#	ARTICLE	IF	CITATIONS
73	When lifestyles sign. Hepatobiliary Surgery and Nutrition, 2019, 8, 69-71.	1.5	2
74	Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk?. Digestive Diseases and Sciences, 2019, 64, 903-909.	2.3	20
75	Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. Journal of Hepatology, 2019, 70, 1019-1023.	3.7	54
76	Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. Journal of Hepatology, 2019, 71, 274-280.	3.7	31
77	Very Low Hepatitis C Viral Loads in Treatment-naïve Persons: Do They Compromise Hepatitis C Virus Antigen Testing?. Clinical Infectious Diseases, 2019, 70, 653-659.	5.8	13
78	IDDF2019-ABS-0134...Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies. , 2019, , .		0
79	938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. American Journal of Gastroenterology, 2019, 114, S546-S546.	0.4	1
80	Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing. Frontiers in Genetics, 2019, 10, 1024.	2.3	6
81	Abnormal T-cell phenotype in episodic angioedema with hypereosinophilia (Gleich's syndrome): frequency, clinical implication and prognosis. Journal of the American Academy of Dermatology, 2019, , .	1.2	9
82	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	13.7	818
83	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1696-1707.	9.4	157
84	Inflammation and Microbiota Fingerprint: Delphi's Oracle for Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma?. Hepatology, 2019, 69, 12-15.	7.3	5
85	Genetic and clinic predictors of new onset diabetes mellitus after transplantation. Pharmacogenomics Journal, 2019, 19, 53-64.	2.0	9
86	Nonalcoholic fatty liver disease burden " Switzerland 2018"2030. Swiss Medical Weekly, 2019, 149, w20152.	1.6	12
87	Smoking favours hepatocellular carcinoma. Annals of Translational Medicine, 2019, 7, S99-S99.	1.7	3
88	Abstract 461: Distinctive molecular traits of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. , 2019, , .		0
89	Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver. Hepatology, 2018, 68, 384-386.	7.3	7
90	Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. Journal of Viral Hepatitis, 2018, 25, 920-929.	2.0	3

#	ARTICLE	IF	CITATIONS
91	FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status. <i>Liver International</i> , 2018, 38, 1468-1474.	3.9	14
92	High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1 patients without cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 293-300.	3.7	127
93	Trends in hepatitis C-related mortality in Switzerland. <i>Journal of Viral Hepatitis</i> , 2018, 25, 152-160.	2.0	18
94	Alternatively spliced tissue factor levels are elevated in the plasma of patients with chronic liver diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1470-1475.	1.6	4
95	IDDF2018-ABS-0109...SOFOSBUVIR/VELPATASVIR for 12 weeks in genotype 1 HCV-infected liver transplant recipients. , 2018, , .		0
96	Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1114-1120.	1.5	41
97	Anti-tumoral effects of exercise on hepatocellular carcinoma growth. <i>Hepatology Communications</i> , 2018, 2, 607-620.	4.3	30
98	Influence of geographical origin on access to therapy and therapy outcomes in hepatitis C virus-infected persons: the Swiss Hepatitis C Cohort Study. <i>Journal of Hepatology</i> , 2018, 68, S169-S170.	3.7	0
99	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4650-4661.	7.0	63
100	Determination of the Endocannabinoids Anandamide and 2-Arachidonoyl Glycerol with Gas Chromatography-Mass Spectrometry: Analytical and Preanalytical Challenges and Pitfalls. <i>Medical Cannabis and Cannabinoids</i> , 2018, 1, 9-18.	3.3	13
101	Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 169-178.	3.7	34
102	Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease. <i>Hepatology Communications</i> , 2018, 2, 933-944.	4.3	21
103	The histidine triad nucleotide-binding protein 2 (HINT2) positively regulates hepatocellular energy metabolism. <i>FASEB Journal</i> , 2018, 32, 5143-5161.	0.5	10
104	Sofosbuvir/velpatasvir for 12 weeks in genotype 1 HCV-infected liver transplant recipients. <i>Journal of Hepatology</i> , 2018, 69, 603-607.	3.7	58
105	Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis. <i>Annals of Transplantation</i> , 2018, 23, 789-801.	0.9	17
106	The effects of obesity on asthma: immunometabolic links. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 469-477.	0.4	35
107	CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. <i>Pharmacogenomics Journal</i> , 2017, 17, 69-75.	2.0	11
108	PTEN Down-Regulation Promotes Oxidation to Fuel Hypertrophic Liver Growth After Hepatectomy in Mice. <i>Hepatology</i> , 2017, 66, 908-921.	7.3	54

#	ARTICLE	IF	CITATIONS
109	Other Extrahepatic Manifestations of Hepatitis C Virus Infection (Pulmonary, Idiopathic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 507 607-629.	2.1	7
110	The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis. Transplantation, 2017, 101, 987-995.	1.0	20
111	Effect of smoking on survival of patients with hepatocellular carcinoma. Liver International, 2017, 37, 1682-1687.	3.9	26
112	Comprehensive NAFLD diagnosis based on a noninvasive metabolomic approach in a liquid biopsy. Journal of Hepatology, 2017, 66, S670-S671.	3.7	0
113	The space ethernet physical layer transceiver (sephy) project: a step towards reliable ethernet in space. IEEE Aerospace and Electronic Systems Magazine, 2017, 32, 24-28.	1.3	5
114	Patients with hepatocellular carcinoma: Your address matters!. Journal of Hepatology, 2017, 66, 480-481.	3.7	1
115	Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. Journal of Hepatology, 2017, 67, 876-878.	3.7	41
116	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. Journal of Hepatology, 2017, 66, S593.	3.7	7
117	Simple non-invasive fibrosis scores identify patients with non-alcoholic fatty liver disease who progress to advanced fibrosis/cirrhosis:evidence from a large cohort of patients with sequential liver biopsies. Journal of Hepatology, 2017, 66, S68-S69.	3.7	0
118	High SVR Rates with Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis. Gastroenterology, 2017, 152, S1059.	1.3	5
119	Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Genotype 1-6 Hepatitis C Virus Infection: An Integrated Analysis. Gastroenterology, 2017, 152, S1089.	1.3	1
120	Omega-3 Fatty Acids Protect Fatty and Lean Mouse Livers After Major Hepatectomy. Annals of Surgery, 2017, 266, 324-332.	4.2	13
121	External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26. Radiation Oncology, 2017, 12, 12.	2.7	8
122	Diagnostic hepatic haemodynamic techniques: safety and radiation exposure. Liver International, 2017, 37, 148-154.	3.9	10
123	The therapeutic landscape of non-alcoholic steatohepatitis. Liver International, 2017, 37, 634-647.	3.9	33
124	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. American Journal of Gastroenterology, 2017, 112, 740-751.	0.4	524
125	Hepatitis C virus infection triggers a tumor-like glutamine metabolism. Hepatology, 2017, 65, 789-803.	7.3	48
126	Nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepatic Oncology, 2017, 4, 83-98.	4.2	9

#	ARTICLE	IF	CITATIONS
127	Management of chronic hepatitis C in 2017. <i>Hamostaseologie</i> , 2017, 37, 186-195.	1.9	3
128	Surveillance for Hepatocellular Carcinoma in Patients with NASH. <i>Diagnostics</i> , 2016, 6, 22.	2.6	30
129	Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. <i>Annals of Hepatology</i> , 2016, 15, 82-90.	1.5	35
130	Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin. <i>Journal of Viral Hepatitis</i> , 2016, 23, 227-231.	2.0	0
131	Two-Step Forward Genetic Screen in Mice Identifies the Ral Pathway as a Central Drug Target in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 151, 231-233.	1.3	1
132	Hepatocellular carcinoma: asphyxiate and then cook. <i>Hepatic Oncology</i> , 2016, 3, 1-3.	4.2	0
133	Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 923-926.	1.6	1
134	Physical activity and liver diseases. <i>Hepatology</i> , 2016, 63, 1026-1040.	7.3	142
135	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1851-1859.	2.8	4
136	Assessment of the Hong Kong Liver Cancer Staging System in Europe. <i>Liver International</i> , 2016, 36, 911-917.	3.9	16
137	Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. <i>Gut</i> , 2016, 65, 1871-1881.	12.1	114
138	Su1422 Efficacy and Safety of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir Without Ribavirin in Patients with HCV Genotype 1b With or Without Compensated Cirrhosis: Pooled Analysis Across 5 Clinical Trials. <i>Gastroenterology</i> , 2016, 150, S1095.	1.3	1
139	EASL/EASD/EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 1388-1402.	3.7	3,403
140	Nutritional stress exacerbates hepatic steatosis induced by deletion of the histidine nucleotide-binding (Hint2) mitochondrial protein. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G497-G509.	3.4	7
141	A strong message is needed to address the issue of HCC recurrence after DAA therapy. <i>Journal of Hepatology</i> , 2016, 65, 1268-1269.	3.7	6
142	The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. <i>Liver International</i> , 2016, 36, 317-324.	3.9	196
143	Treatment of Non-Alcoholic Fatty Liver Disease. <i>Digestive Diseases</i> , 2016, 34, 27-31.	1.9	22
144	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 877-889.	3.7	70

#	ARTICLE	IF	CITATIONS
145	Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues from Patients. <i>Gastroenterology</i> , 2016, 151, 513-525.e0.	1.3	180
146	Tu1663 The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. <i>Gastroenterology</i> , 2016, 150, S1161.	1.3	0
147	Fulminant hepatic and multiple organ failure following acute viral tonsillitis: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 7.	0.8	2
148	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1168-1176.	2.8	44
149	Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach. <i>Journal of Viral Hepatitis</i> , 2016, 23, 697-707.	2.0	3
150	A significant effect of the killer cell immunoglobulin-like receptor ligand human leucocyte antigen on fibrosis progression in chronic C hepatitis with or without liver transplantation. <i>Liver International</i> , 2016, 36, 1331-1339.	3.9	4
151	Time to Abandon NASH?. <i>Hepatology</i> , 2016, 63, 9-10.	7.3	18
152	Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients. <i>Journal of Neurology</i> , 2016, 263, 981-990.	3.6	54
153	Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). <i>Annals of Oncology</i> , 2016, 27, 856-861.	1.2	107
154	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 685-697.	9.1	402
155	Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfecting men who have sex with men. <i>Journal of Hepatology</i> , 2016, 65, 26-32.	3.7	26
156	Hepatocellular carcinoma and lifestyles. <i>Journal of Hepatology</i> , 2016, 64, 203-214.	3.7	93
157	Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations. <i>PLoS ONE</i> , 2016, 11, e0155464.	2.5	9
158	Cellular and molecular effects of the mTOR inhibitor everolimus. <i>Clinical Science</i> , 2015, 129, 895-914.	4.3	74
159	Molecular epidemiology of hepatitis B virus infection in Switzerland: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2015, 15, 483.	2.9	17
160	T and B cell responses and previous exposure to hepatitis B virus in anti-HBc alone™ patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 1068-1078.	2.0	13
161	Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. <i>Hepatology</i> , 2015, 62, 158-165.	7.3	225
162	A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2015, 62, 1375-1387.	7.3	25

#	ARTICLE	IF	CITATIONS
163	99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin. <i>American Journal of Gastroenterology</i> , 2015, 110, S850-S851.	0.4	4
164	STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2015, 62, 1246-1255.	3.7	19
165	Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1057-1064.	2.8	4
166	Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. <i>Journal of Hepatology</i> , 2015, 62, 1296-1303.	3.7	92
167	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 859-870.	10.7	699
168	Separation of small metabolites and lipids in spectra from biopsies by diffusion-weighted HR-MAS NMR: a feasibility study. <i>Analyst</i> , The, 2015, 140, 272-279.	3.5	14
169	Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude. <i>Seminars in Liver Disease</i> , 2015, 35, 304-317.	3.6	50
170	Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 67-76.	3.3	35
171	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , 2015, 64, 322-331.	12.1	30
172	Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND, a Phase 2b study. <i>Liver International</i> , 2015, 35, 417-421.	3.9	18
173	Impact of common risk factors of fibrosis progression in chronic hepatitis C. <i>Gut</i> , 2015, 64, 1605-1615.	12.1	85
174	Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. <i>Genes and Cancer</i> , 2015, 6, 317-327.	1.9	5
175	Hepatitis C: a changing epidemic. <i>Swiss Medical Weekly</i> , 2015, 145, w14093.	1.6	32
176	Factors affecting screening for hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2014, 13, 204-210.	1.5	14
177	Communication aspects in wireless passive sensing on spacecrafts. , 2014, , .		2
178	Everolimus is a potent inhibitor of activated hepatic stellate cell functions <i>in vitro</i> and <i>in vivo</i> , while demonstrating anti-angiogenic activities. <i>Clinical Science</i> , 2014, 126, 775-791.	4.3	20
179	Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma. <i>Clinical Science</i> , 2014, 126, 243-252.	4.3	23
180	Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon and ribavirin in chronic hepatitis C virus patients. <i>Liver International</i> , 2014, 34, 551-557.	3.9	13

#	ARTICLE	IF	CITATIONS
181	Reduced IFN α 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. <i>Nature Communications</i> , 2014, 5, 5699.	12.8	117
182	Sorafenib for once a day is not an issue. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 273-274.	17.8	4
183	Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1927.	7.4	89
184	The Interactions of Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. <i>Clinics in Liver Disease</i> , 2014, 18, 233-248.	2.1	18
185	Wireless Passive Sensors for Remote Sensing of Temperature on Aerospace Platforms. <i>IEEE Sensors Journal</i> , 2014, 14, 3883-3892.	4.7	12
186	Disruption of tumor suppressor gene Hint1 leads to remodeling of the lipid metabolic phenotype of mouse liver. <i>Journal of Lipid Research</i> , 2014, 55, 2309-2319.	4.2	7
187	The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 568-577.	2.0	19
188	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014, 5, 4309.	12.8	478
189	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014, 61, 482-491.	3.7	18
190	Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 75-81.	3.7	431
191	Management of hepatocellular carcinoma: time to be resilient. <i>Hepatic Oncology</i> , 2014, 1, 261-263.	4.2	0
192	Sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC): A randomized multicenter phase II trial (SAKK 77/08 and SASL 29).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4099-4099.	1.6	1
193	Factors affecting screening for hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2014, 13, 204-10.	1.5	4
194	Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. <i>Journal of Hepatology</i> , 2013, 58, 669-675.	3.7	41
195	Characterization of the Effect of the Mitochondrial Protein Hint2 on Intracellular Ca ²⁺ dynamics. <i>Biophysical Journal</i> , 2013, 105, 1268-1275.	0.5	15
196	Wireless passive sensors for remote sensing of temperature on aerospace platforms. , 2013, , .		5
197	An Overview of the Smart Sensor Inter-agency Reference Testbench (SSIART). , 2013, , .		3
198	An Uncommon Cause of a Focal Liver Lesion. <i>Gastroenterology</i> , 2013, 144, 510-659.	1.3	8

#	ARTICLE	IF	CITATIONS
199	Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 504-509.	3.7	73
200	Modern Hepatomancy. <i>Gastroenterology</i> , 2013, 144, 876-878.	1.3	2
201	504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS. <i>Journal of Hepatology</i> , 2013, 58, S207.	3.7	3
202	Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. <i>European Journal of Pharmacology</i> , 2013, 705, 86-95.	3.5	38
203	Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification. <i>Hepatology</i> , 2013, 58, 229-238.	7.3	172
204	IL28B expression depends on a novel TT/G polymorphism which improves HCV clearance prediction. <i>Journal of Experimental Medicine</i> , 2013, 210, 1109-1116.	8.5	193
205	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Seminars in Liver Disease</i> , 2013, 32, 348-359.	3.6	508
206	Intermediate hepatocellular carcinoma: current treatments and future perspectives. <i>Annals of Oncology</i> , 2013, 24, 24-29.	1.2	70
207	Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development. <i>PLoS ONE</i> , 2013, 8, e64053.	2.5	59
208	C-reactive protein, a prognostic marker in hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2103-2105.	7.3	12
209	Disruption of the histidine triad nucleotide-binding <i>hint2</i> gene in mice affects glycemic control and mitochondrial function. <i>Hepatology</i> , 2013, 57, 2037-2048.	7.3	31
210	Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial. <i>American Journal of Gastroenterology</i> , 2013, 108, S145.	0.4	2
211	Hepatocellular carcinoma in a non-cirrhotic patient with Wilson's disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 2110.	3.3	22
212	Potentials and pitfalls of clinical peptidomics and metabolomics. <i>Swiss Medical Weekly</i> , 2013, 143, w13801.	1.6	26
213	The Vitamin D Receptor Gene <i>Bat</i> (<i>Cca</i>) Haplotype Impairs the Response to Pegylated-Interferon/Ribavirin-Based Therapy in Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2012, 17, 541-547.	1.0	29
214	Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2584.	7.4	1,327
215	Biomarkers for Hepatocellular Apoptosis in the Management of Liver Diseases. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 2221-2227.	1.6	5
216	Urogenital Manifestations in Wegener Granulomatosis. <i>Medicine (United States)</i> , 2012, 91, 67-74.	1.0	56

#	ARTICLE	IF	CITATIONS
217	Treatment of NASH with ursodeoxycholic acid: Cons. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, S46-S52.	1.5	10
218	EASLâ€EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 908-943.	3.7	5,214
219	TACE with or without systemic therapy?. Journal of Hepatology, 2012, 56, 1224-1225.	3.7	22
220	Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. Journal of Hepatology, 2012, 57, 592-599.	3.7	28
221	EASLâ€EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. European Journal of Cancer, 2012, 48, 599-641.	2.8	406
222	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 2012, 143, 1244-1252.e12.	1.3	142
223	A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C. PLoS ONE, 2012, 7, e40159.	2.5	60
224	Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology, 2012, 55, 1038-1047.	7.3	36
225	Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2012, 19, 568-573.	2.0	16
226	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology, 2012, 55, 384-394.	7.3	138
227	Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. Swiss Medical Weekly, 2012, 142, w13516.	1.6	9
228	Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. Swiss Medical Weekly, 2012, 142, w13651.	1.6	11
229	Primary Hepatocellular Carcinoma. Molecular Pathology Library, 2011, , 831-848.	0.1	0
230	Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Plasma Metabolomics and Lipid Profiling. Cancer Research, 2011, 71, 6590-6600.	0.9	243
231	UDCA for NASH: End of the story?. Journal of Hepatology, 2011, 54, 856-858.	3.7	26
232	Abnormal nitrosothiol metabolism in hepatocellular carcinoma. Journal of Hepatology, 2011, 54, 579-580.	3.7	2
233	PI(3)K/PTEN/AKT pathway. Journal of Hepatology, 2011, 54, 1317-1319.	3.7	22
234	Viral genotype-specific role of PNPLA3 , PPARG , MTP, and IL28B in hepatitis C virus-associated steatosis. Journal of Hepatology, 2011, 55, 529-535.	3.7	98

#	ARTICLE	IF	CITATIONS
235	Hit proteins, mitochondria and cancer. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2011, 1807, 626-632.	1.0	52
236	Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?. <i>Liver Transplantation</i> , 2011, 17, S109-S116.	2.4	46
237	Ablation of the tumor suppressor histidine triad nucleotide binding protein 1 is protective against hepatic ischemia/reperfusion injury. <i>Hepatology</i> , 2011, 53, 243-252.	7.3	10
238	Effect of sorafenib on murine liver regeneration. <i>Hepatology</i> , 2011, 53, 577-586.	7.3	31
239	Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1007-1017.	4.1	72
240	Biology of Hepatocellular Carcinoma. , 2011, , 21-34.		0
241	Management of hepatitis C virus (HCV) infection in drug substitution programs. <i>Swiss Medical Weekly</i> , 2011, 141, w13193.	1.6	16
242	Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. <i>Clinical Science</i> , 2010, 118, 401-410.	4.3	76
243	Significance of serum adiponectin levels in patients with chronic liver disease. <i>Clinical Science</i> , 2010, 119, 431-436.	4.3	47
244	Vitamin E for nonalcoholic steatohepatitis: Ready for prime time?. <i>Hepatology</i> , 2010, 52, 789-792.	7.3	9
245	Treat the bones and get less rejection!. <i>Liver International</i> , 2010, 30, 337-338.	3.9	0
246	Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2010, 17, 845-850.	2.0	14
247	Macro-AST in an asymptomatic young patient. <i>Annals of Hepatology</i> , 2010, 9, 93-95.	1.5	19
248	Acute Ophthalmoparesis Associated with Human Parvovirus B19 Infection. <i>European Journal of Ophthalmology</i> , 2010, 20, 802-804.	1.3	10
249	Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study. <i>Oncologist</i> , 2010, 15, 1198-1204.	3.7	87
250	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. <i>Gastroenterology</i> , 2010, 138, 1338-1345.e7.	1.3	1,056
251	Hepatoprotective effect of tumour necrosis factor α blockade in psoriatic arthritis: a cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1148-1150.	0.9	34
252	VEGF Signaling. , 2010, , 421-437.		1

#	ARTICLE	IF	CITATIONS
253	Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. <i>Swiss Medical Weekly</i> , 2010, 140, w13055.	1.6	4
254	Macro-AST in an asymptomatic young patient. <i>Annals of Hepatology</i> , 2010, 9, 93-5.	1.5	7
255	Ocular zoonoses. <i>Expert Review of Ophthalmology</i> , 2009, 4, 331-349.	0.6	2
256	Pegylated interferon α _{2a} /ribavirin treatment of recurrent hepatitis C after liver transplantation. <i>Transplant Infectious Disease</i> , 2009, 11, 33-39.	1.7	22
257	Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2009, 29, 1184-1188.	3.9	66
258	Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. <i>Journal of Hepatology</i> , 2009, 51, 655-666.	3.7	247
259	The evasive promise of antiangiogenic therapy. <i>Journal of Hepatology</i> , 2009, 51, 970-972.	3.7	4
260	Severe autoimmune cytopenias in treatment-naïve hepatitis C virus infection: clinical description of 16 cases. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 245-253.	1.6	22
261	Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. <i>Liver International</i> , 2008, 28, 370-376.	3.9	31
262	Dual induction of PKR with E2F-1 and IFN- λ to enhance gene therapy against hepatocellular carcinoma. <i>Cancer Gene Therapy</i> , 2008, 15, 636-644.	4.6	10
263	O tempora, o mores cancrorum. <i>Liver International</i> , 2008, 28, 153-154.	3.9	0
264	Disproportionally high results of transient elastography in patients with autoimmune hepatitis. <i>Liver International</i> , 2008, 28, 1177-1178.	3.9	29
265	Autoimmune hemolytic anemia: classification and therapeutic approaches. <i>Expert Review of Hematology</i> , 2008, 1, 189-204.	2.2	20
266	Corrigendum to "Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma" [Hepatology 46 (2007) 840-848]. <i>Journal of Hepatology</i> , 2008, 48, 684.	3.7	2
267	Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008, 49, 78-87.	3.7	89
268	Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. <i>Gut</i> , 2008, 57, 1597-1603.	12.1	41
269	Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1743-1749.	2.4	76
270	Hint2 Is Expressed in the Mitochondria of H295R Cells and Is Involved in Steroidogenesis. <i>Endocrinology</i> , 2008, 149, 5461-5469.	2.8	16

#	ARTICLE	IF	CITATIONS
271	Targeting vessels to treat hepatocellular carcinoma. <i>Clinical Science</i> , 2008, 114, 467-477.	4.3	12
272	Tumor suppressor and hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2008, 14, 1720.	3.3	71
273	Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2007, 46, 840-848.	3.7	215
274	Met-thodology. <i>Journal of Hepatology</i> , 2007, 46, 748-749.	3.7	1
275	Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes in the murine liver. <i>Journal of Hepatology</i> , 2007, 47, 538-545.	3.7	20
276	NASH and thiazolidinediones: Not to be taken lightly. <i>Journal of Hepatology</i> , 2007, 47, 451-453.	3.7	9
277	Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. <i>Journal of Drug Targeting</i> , 2007, 15, 623-631.	4.4	27
278	Bridging hyperacute liver failure by ABO-incompatible auxiliary partial orthotopic liver transplantation. <i>Transplant International</i> , 2007, 20, 722-727.	1.6	5
279	Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. <i>Liver International</i> , 2007, 27, 764-771.	3.9	49
280	Hint2, A Mitochondrial Apoptotic Sensitizer Down-Regulated in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2006, 130, 2179-2188.	1.3	53
281	Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1537-1543.	4.4	311
282	What is the current treatment of PTLT after liver transplantation?. <i>Journal of Hepatology</i> , 2006, 44, 23-26.	3.7	20
283	Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1117-1119.	1.6	22
284	Microfabrication and characterization of an ion-selective microelectrode array platform. <i>Sensors and Actuators B: Chemical</i> , 2005, 105, 65-73.	7.8	19
285	Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition. <i>Hepatology</i> , 2005, 41, 1241-1251.	7.3	14
286	Unusual evolution of posterior reversible encephalopathy syndrome (PRES) one year after liver transplantation. <i>Liver Transplantation</i> , 2005, 11, 588-590.	2.4	7
287	Vascular Endothelial Growth Factor Signaling. , 2005, , 91-104.		4
288	Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2005, 42, 41-46.	3.7	151

#	ARTICLE	IF	CITATIONS
289	Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2004, 287, R1505-R1516.	1.8	57
290	A comparison of three models of the inositol trisphosphate receptor. <i>Progress in Biophysics and Molecular Biology</i> , 2004, 85, 121-140.	2.9	37
291	The Bile Acid Nuclear Receptor FXR and the Bile Acid Binding Protein IBABP Are Differently Expressed in Colon Cancer. <i>Digestive Diseases and Sciences</i> , 2004, 49, 982-989.	2.3	109
292	Cholestasis shuts down calcium signaling in cholangiocytes. <i>Hepatology</i> , 2004, 39, 248-249.	7.3	4
293	Nontumoral dermatologic problems after liver transplantation. <i>Liver Transplantation</i> , 2004, 10, 331-339.	2.4	16
294	Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. <i>Journal of Hepatology</i> , 2004, 40, 305-312.	3.7	63
295	Angiogenesis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 41, 864-880.	3.7	322
296	Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases. <i>Medical Hypotheses</i> , 2004, 62, 82-85.	1.5	7
297	Herpes simplex virus hepatitis 4 years after liver transplantation. <i>Journal of Gastroenterology</i> , 2003, 38, 1005-1008.	5.1	33
298	Effect of VEGF and endostatin gene transfer on the time course expression of endoglin after partial hepatectomy in a mouse model. <i>Gastroenterology</i> , 2003, 124, A726.	1.3	0
299	Hepatocellular antifreeze carrier. <i>Journal of Hepatology</i> , 2003, 39, 460-462.	3.7	2
300	Vasopressin Type 1A Receptor Up-regulation by Cyclosporin A in Vascular Smooth Muscle Cells Is Mediated by Superoxide. <i>Journal of Biological Chemistry</i> , 2003, 278, 41685-41690.	3.4	11
301	Spontaneous Regression of an Inflammatory Pseudotumor of the Liver. <i>Zeitschrift Fur Gastroenterologie</i> , 2003, 41, 991-994.	0.5	13
302	Congenital dyserythropoietic anaemia type II (HEMPAS) and haemochromatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 1141-1147.	1.6	10
303	Image of the month. <i>Gastroenterology</i> , 2003, 125, 1010-1010.	1.3	4
304	Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. <i>Swiss Medical Weekly</i> , 2003, 133, 455-60.	1.6	7
305	Preoperative Galactose Elimination Capacity Predicts Complications and Survival After Hepatic Resection. <i>Annals of Surgery</i> , 2002, 235, 77-85.	4.2	92
306	A dynamic model of the type-2 inositol trisphosphate receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 2398-2403.	7.1	109

#	ARTICLE	IF	CITATIONS
307	Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare. <i>Journal of Hepatology</i> , 2002, 37, 748-752.	3.7	15
308	Identification of a hepatic protein which interacts with the IP3 receptor and regulates calcium signals. <i>Journal of Hepatology</i> , 2002, 36, 6.	3.7	0
309	Adenovirus-mediated gene transfer of VEGF and endostatin influences liver regeneration in mice. <i>Journal of Hepatology</i> , 2002, 36, 79.	3.7	0
310	Activity of CYP2E1 measured by the chlorzoxazone test in patients with non-alcoholic steatohepatitis and activation of stellate cells. <i>Journal of Hepatology</i> , 2002, 36, 146.	3.7	2
311	Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare. <i>Journal of Hepatology</i> , 2002, 36, 152-153.	3.7	0
312	Survival pathways and preconditioning in liver transplantation. <i>Transplant Immunology</i> , 2002, 9, 239-241.	1.2	3
313	Liver Surgery in the Era of Tissue-preserving Resections: Early and Late Outcome in Patients with Primary and Secondary Hepatic Tumors. <i>World Journal of Surgery</i> , 2002, 26, 1126-1132.	1.6	50
314	Interferon and amantadine in naive chronic hepatitis C: A double-blind, randomized, placebo-controlled trial. <i>Hepatology</i> , 2002, 35, 447-454.	7.3	36
315	Extended preservation of rat liver graft by induction of heme oxygenase-1. <i>Hepatology</i> , 2002, 35, 1082-1092.	7.3	89
316	Regulation of Ca ²⁺ signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms. <i>Hepatology</i> , 2002, 36, 284-296.	7.3	79
317	Expression and regulation of gap junctions in rat cholangiocytes. <i>Hepatology</i> , 2002, 36, 631-640.	7.3	66
318	Liver allocation in Switzerland. <i>Liver Transplantation</i> , 2002, 8, 88-88.	2.4	0
319	Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. <i>Swiss Medical Weekly</i> , 2002, 132, 493-505.	1.6	18
320	1 α ,25-Dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts. <i>Hepatology</i> , 2001, 34, 926-934.	7.3	58
321	Alternative splice variants of hTrp4 differentially interact with the C-terminal portion of the inositol 1,4,5-trisphosphate receptors. <i>FEBS Letters</i> , 2001, 487, 377-383.	2.8	68
322	Rat inositol 1,4,5-trisphosphate receptor isoform 2 interacts with itself in its C-terminal portion and upstream of the first transmembrane domain. <i>FEBS Journal</i> , 2001, 268, 5981-5988.	0.2	3
323	Alagille syndrome with colonic polyposis. <i>American Journal of Gastroenterology</i> , 2001, 96, 2775-2777.	0.4	5
324	Expression of Intracellular Calcium Channels and Pumps after Partial Hepatectomy in Rat. <i>Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications</i> , 2000, 3, 374-379.	1.6	17

#	ARTICLE	IF	CITATIONS
325	Primary liver disease as a determinant for acute rejection after liver transplantation. <i>Langenbeck's Archives of Surgery</i> , 1999, 384, 259-263.	1.9	17
326	Expression of inositol 1,4,5-trisphosphate receptor isoforms in rat cirrhosis. <i>Hepatology</i> , 1999, 30, 1018-1026.	7.3	36
327	Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. <i>Digestive Diseases and Sciences</i> , 1998, 43, 2573-2576.	2.3	108
328	Inositol 1,4,5-Trisphosphate and Calcium Regulate the Calcium Channel Function of the Hepatic Inositol 1,4,5-Trisphosphate Receptor. <i>Journal of Biological Chemistry</i> , 1997, 272, 2675-2681.	3.4	70
329	Reversibility of Hepatic Fibrosis in Autoimmune Hepatitis. <i>Annals of Internal Medicine</i> , 1997, 127, 981.	3.9	264
330	Botulinum toxin injection for secondary achalasia with esophageal varices. <i>Gastrointestinal Endoscopy</i> , 1997, 45, 191-193.	1.0	9
331	Disruption of actin organization by cytochalasin D does not impair biliary secretion of organic anions in the rat. <i>Hepatology</i> , 1997, 25, 970-975.	7.3	10
332	Stimulation of bile acid independent bile flow with bromo-cyclic guanosine monophosphate. <i>Hepatology</i> , 1996, 24, 1487-1491.	7.3	11
333	Methotrexate Therapy and Liver Disease. <i>New England Journal of Medicine</i> , 1996, 335, 898-899.	27.0	6
334	Increased hepatic lysosomal activity in biliary cirrhosis originates from hepatocytes rather than from macrophages. <i>Journal of Hepatology</i> , 1994, 20, 524-530.	3.7	8
335	Dubin-Johnson-like Syndrome in Golden Lion Tamarins (<i>Leontopithecus rosalia rosalia</i>). <i>Veterinary Pathology</i> , 1993, 30, 491-498.	1.7	20
336	Alterations in hepatic fructose metabolism in cirrhotic patients demonstrated by dynamic ³¹ P phosphorus spectroscopy. <i>Hepatology</i> , 1992, 15, 835-842.	7.3	26
337	Hepatic accumulation of lysosomes and defective transcytotic vesicular pathways in cirrhotic rat liver. <i>Hepatology</i> , 1992, 16, 997-1006.	7.3	16
338	Ion-selective microelectrode array for intracellular detection on chip. , 0, , .		2
339	Hepatic manifestations of drug reaction with eosinophilia and systemic symptoms syndrome. <i>Exploration of Medicine</i> , 0, , .	1.5	0
340	Biliary Epithelial Cells. , 0, , 52-57.		0
341	Medical Problems after Liver Transplantation. , 0, , 395-418.		1